{
  "nctId": "NCT03615326",
  "briefTitle": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)",
  "officialTitle": "A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)",
  "protocolDocument": {
    "nctId": "NCT03615326",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2022-09-08",
    "uploadDate": "2025-03-04T14:01",
    "size": 4826864,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03615326/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 738,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-10-05",
    "completionDate": "2025-11-12",
    "primaryCompletionDate": "2024-03-20",
    "firstSubmitDate": "2018-07-31",
    "firstPostDate": "2018-08-03"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nInclusion criteria include, but are not limited to:\n\n* Histologically or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2) positive gastric or gastroesophageal junction (GEJ) adenocarcinoma\n* HER2-positive defined as either immunohistochemistry (IHC) 3+ or IHC 2+ in combination with in-situ hybridization positive (ISH+) or fluorescent in-situ hybridization (FISH), as assessed by central review on primary or metastatic tumor\n* Has measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the site investigator\n* Male participants must agree to use approved contraception\n* Female participants who are not pregnant or breastfeeding, and who are either not a woman of childbearing potential (WOCBP), or are a WOCBP who agrees to use approved contraception\n* Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale within 3 days prior to the first dose of trial treatment\n* Has a life expectancy of greater than 6 months\n* Has adequate organ function\n\nExclusion Criteria:\n\nExclusion criteria include, but are not limited to:\n\n* Has had previous therapy for locally advanced unresectable or metastatic gastric/GEJ cancer\n* Has had major surgery, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment\n* Has had radiotherapy within 14 days of randomization\n* Has a known additional malignancy that is progressing or has required active treatment within the past 5 years\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has an active autoimmune disease that has required systemic treatment in past 2 years\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy\n* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis\n* Has a known history of active tuberculosis (TB; Mycobacterium tuberculosis)\n* Has an active infection requiring systemic therapy\n* Has poorly controlled diarrhea\n* Accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment. If the participant is receiving diuretic drugs for other reasons, it is acceptable\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator\n* Has peripheral neuropathy \\> Grade 1\n* Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial\n* A WOCBP who has a positive urine pregnancy test within 24 hours prior to randomization or treatment allocation\n* Has active or clinically significant cardiac disease\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection\n* Has severe hypersensitivity (â‰¥Grade 3) to pembrolizumab, trastuzumab, study chemotherapy agents and/or to any excipients, murine proteins, or platinum-containing products\n* Has had an allogeneic tissue/solid organ transplant\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 \\[CTLA-4\\], OX 40, Cluster of Differentiation 137 \\[CD137\\])",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICR",
        "description": "PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. PFS was determined for first course pembrolizumab in the Global Cohort. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis.",
        "timeFrame": "Up to 46 months"
      },
      {
        "measure": "Overall Survival (OS)",
        "description": "OS is defined as the time from randomization to death due to any cause. OS was determined for first course pembrolizumab in the Global Cohort. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis.",
        "timeFrame": "Up to 63 months"
      }
    ],
    "secondary": [
      {
        "measure": "Objective Response Rate (ORR) Per RECIST 1.1 Assessed by BICR",
        "description": "ORR is defined as the percentage of participants who have a Complete Response (\\[CR\\], disappearance of all evidence of disease) or Partial Response (\\[PR\\], regression of measurable disease and no new sites) per RECIST 1.1 as assessed by blinded independent central review (BICR). ORR was determined for first course pembrolizumab in the Global Cohort. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis.",
        "timeFrame": "Up to 63 months"
      },
      {
        "measure": "Duration of Response (DOR) Per RECIST 1.1 Assessed by BICR",
        "description": "For participants who demonstrate CR or PR, DOR is defined as the time from first response (CR or PR) to subsequent disease progression or death from any cause, whichever occurs first. DOR was determined for first course pembrolizumab in the Global Cohort. Per statistical analysis plan, participants in the Japan-specific SOX Cohort were not included in the efficacy analysis.",
        "timeFrame": "Up to 63 months"
      },
      {
        "measure": "Number of Participants Who Experienced an Adverse Event (AE)",
        "description": "An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who experienced an AE is reported for each treatment arm. Per statistical analysis plan, data from the second course of pembrolizumab was not included in the safety analysis.",
        "timeFrame": "Up to 63 months"
      },
      {
        "measure": "Number of Participants Who Discontinued Study Treatment Due to AEs",
        "description": "An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who discontinued study treatment due to an AE is reported for each treatment arm. Per statistical analysis plan, data from the second course of pembrolizumab was not included in the safety analysis.",
        "timeFrame": "Up to 63 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 4,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 69,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:44.104Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}